COMMUNICATION
Synthesis and characterization of a smart contrast agent sensitive to
calciumw
Kirti Dhingra,*a Martin E. Maier,b Michael Beyerlein,a Goran Angelovskia
and Nikos K. Logothetis*ac
Received (in Cambridge, UK) 4th February 2008, Accepted 25th April 2008
First published as an Advance Article on the web 4th June 2008
DOI: 10.1039/b801975d
A novel first-generation Ca2+ sensitive contrast agent, Gd-
DOPTRA has been synthesized and characterized. The agent
proposed a potential MRI contrast agent, Gd-DOPTA
which is sensitive to Ca2+ concentration in the 0.1–10 mM
range with an apparent dissociation constant of 0.96 mM.6
We recently reported a modification of Gd-DOPTA which
shows B100% relaxivity enhancement upon addition of Ca2+
.
The agent is selective and sensitive to Ca2+ also in the presence
of Mg2+ and Zn2+. The relaxivity studies carried out in
physiological fluids prove the prospects of the agent for in vivo
measurements.
is suitable for [Ca2+
] measurement, however the relaxivity
o
response of this probe to Ca2+ is too low for in vivo measure-
ments.7
With the objective of tracking the modulation in Ca2+ with
a high relaxivity response, we synthesized a novel calcium
sensitive MRI contrast agent, Gd-DOPTRA. Gd-DOPTRA
has proven to be both selective and sensitive to Ca2+ over its
competitor cation Mg2+, with a relaxivity response of B100%
on addition of Ca2+. Gd-DOPTRA has been designed by
exploiting the Ca2+ chelating properties of APTRA (o-amino-
phenol-N,N,O-triacetate) linked to a Gd3+ loaded DO3A
unit. The choice of a low affinity pentadentate Ca2+ chelator,
APTRA (Kd = 20–25 mM)8 was made because high affinity
chelators (such as BAPTA, Kd = 0.1–0.4 mM) would most
likely result in saturation of the indicator when the calcium
concentration ([Ca2+]) increases above 1 mM. Further, due to
their slow kinetics, they have limited ability to follow rapid
changes in [Ca2+] and significantly contribute to Ca2+ buffer-
ing capacity.9 Low affinity chelators have been reported to
show fewer problems with local saturation, Ca2+ binding
kinetics, and Ca2+ buffering.9 Another advantage of choosing
APTRA as chelator is to simplify the overall synthesis of the
contrast agent (CA) with just a simple seven-step synthesis
(Scheme 1).
After the first report of Ca2+ as a signaling molecule in
muscles, its role as a carrier of information has been recog-
nized and this fact has invaded all corners of biology from
biochemistry to cell biology and biophysics.1 Ca2+ plays an
important dual role as a carrier of electrical current and as a
second messenger in the brain. Since its actions are mediated
by a large array of proteins including protein kinases, the
effects are much more diverse than that of the other second
messengers such as cAMP (30,50-cyclic adenosine monophos-
phate) and DAG (diacylglycerol).2 The concentration of Ca2+
outside the cell ([Ca2+]o) is 1.5–2 mM while it is only 50–100
nM inside the cells resulting in an extreme Ca2+ gradient of
15 000–40 000:1, outside to inside.3 Studies done using ion
selective micropipettes have shown that during normal brain
activity, the [Ca2+]o decreases B15%. However, during max-
imal stimulation, [Ca2+
] drops 30% while under traumatic
o
events such as epileptic seizures and terminal anoxia it can
decrease up to 90%.4 The modulation in Ca2+ concentrations,
both inside and outside the cell is a significant factor in
determining nervous system function in both the normal
as well as in pathological conditions.5 Development of
fluorescent dyes has greatly added to our understanding of
this critical role played by Ca2+. However the depth penetra-
tion limit of optical imaging techniques and production of
toxic photobleaching byproducts of fluorescent dyes stimu-
lated the development of ‘smart contrast agents’ for
MRI which can provide information about physiological
signals and biochemical events noninvasively and with
high spatial resolution.6 Along these lines, Li et al. have
The synthesis started with 2-nitroresorcinol which was
monobenzylated using benzyl bromide giving 1 in 85% yield.
Alkylation of phenol 1 was done with 1,3-dibromopropane to
give the alkyl bromide 2 in 88% yield. This was then used for
alkylation of tris-tert-Bu-DO3A to give the macrocycle 4 in
66% yield. Thereafter, the NO2 group was reduced with
simultaneous removal of the benzyl group by hydrogenation
using Pd–C as the catalyst to obtain 5 in 85% yield. The tris-
tert-butylester 5 was then hydrolysed in neat TFA to give
triacid 6 in 68% yield. As the alkylation of aniline 5 with tert-
butylbromoacetate or with methylbromoacetate was not suc-
cessful, yielding a mixture of two products which were difficult
to separate, 7 was finally obtained in moderate yield by
alkylation of 6 with bromoacetic acid and NaOH. The ligand
7 was purified by RP-HPLC and loaded with Ln3+ (Gd3+ or
Eu3+) using LnCl3ꢀ6H2O in water at pH 7. The final concen-
tration of Gd3+ was determined by ICP-OES. Obtained
complexes once formed were stable, however very slow hydro-
lysis of one acetate arm was observed similarly to a previously
a Max Planck Institute for Biological Cybernetics, Department of
Physiology of Cognitive Processes, Tubingen, Germany.
¨
E-mail: Kirti.Dhingra@tuebingen.mpg.de,
Nikos.Logothetis@tuebingen.mpg.de; Fax: 00 49 7071 601 919;
Tel: 00 49 7071 601 917
b Institut fur Organische Chemie, University of Tubingen, Tubingen,
Germany
¨
¨
¨
c Imaging Science and Biomedical Engineering, University of
Manchester, Manchester, UK
w Electronic supplementary information (ESI) available: Experimental
section. See DOI: 10.1039/b801975d
ꢁc
This journal is The Royal Society of Chemistry 2008
3444 | Chem. Commun., 2008, 3444–3446